Cargando…

COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes

OBJECTIVES: To explore factors that are associated with reactogenicity in general and systemic after the first dose of COVID-19 vaccine in the Netherlands. DESIGN: A web-based prospective cohort design using patient reported outcomes (PROs). SETTING: Any person who has been vaccinated with any brand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rolfes, Leàn, Härmark, Linda, Kant, Agnes, van Balveren, Leontine, Hilgersom, Wil, van Hunsel, Florence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761555/ https://www.ncbi.nlm.nih.gov/pubmed/35067381 http://dx.doi.org/10.1016/j.vaccine.2022.01.013

Ejemplares similares

Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands
por: Kant, Agnes, et al.
Publicado: (2022)

Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
por: Duijster, Janneke W., et al.
Publicado: (2023)

The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
por: Rolfes, Leàn, et al.
Publicado: (2016)

Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands
por: van der Boor, Saskia C., et al.
Publicado: (2023)

Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
por: Kant, Agnes, et al.
Publicado: (2022)

Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
por: Härmark, Linda, et al.
Publicado: (2020)

Correction to: Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
por: Härmark, Linda, et al.
Publicado: (2020)

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
por: Kemmeren, J. M., et al.
Publicado: (2021)

Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience
por: Oosterhuis, Ingrid, et al.
Publicado: (2022)

Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre
por: Watson, Sarah, et al.
Publicado: (2017)

Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis
por: van Hoof, Monica, et al.
Publicado: (2022)

The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis
por: Rolfes, Leàn, et al.
Publicado: (2017)

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
por: Hensley, Kathryn S., et al.
Publicado: (2022)

Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database
por: Rolfes, Leàn, et al.
Publicado: (2018)

Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study
por: Hensley, Kathryn S., et al.
Publicado: (2023)

Adverse Drug Reactions of Intranasal Corticosteroids in the Netherlands: An Analysis from the Netherlands Pharmacovigilance Center
por: Rollema, Corine, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
por: Fratzke, Alycia P., et al.
Publicado: (2022)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

Motives for reporting adverse drug reactions by patient-reporters in the Netherlands
por: van Hunsel, Florence, et al.
Publicado: (2010)

Red yeast rice (Monascus purpureus) supplements: Case series assessment of spontaneously reported cases to The Netherlands Pharmacovigilance Centre Lareb
por: Vrolijk, Misha F., et al.
Publicado: (2020)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

Intensive monitoring of duloxetine: results of a web-based intensive monitoring study
por: Härmark, Linda, et al.
Publicado: (2012)

An evaluation of postmarketing reports of hyperglycaemia associated with dolutegravir for treatment of HIV in Eswatini
por: Duga, Alemayehu L., et al.
Publicado: (2022)

Cohort Event Monitoring of Adverse Reactions to COVID-19 Vaccines in Seven European Countries: Pooled Results on First Dose
por: Raethke, Monika, et al.
Publicado: (2023)

A prediction model‐based algorithm for computer‐assisted database screening of adverse drug reactions in the Netherlands
por: Scholl, Joep H.G., et al.
Publicado: (2017)

In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines
por: Molenaar-de Backer, Marijke W. A., et al.
Publicado: (2023)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Reactogenicity to COVID-19 vaccination in the United States of America
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Editorial: Non-reactogenic vaccines against Q-fever
por: Gregory, Anthony E., et al.
Publicado: (2023)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

What Future Healthcare Professionals Need to Know About Pharmacovigilance: Introduction of the WHO PV Core Curriculum for University Teaching with Focus on Clinical Aspects
por: van Eekeren, Rike, et al.
Publicado: (2018)

Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study
por: Naranbhai, Vivek, et al.
Publicado: (2022)

Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands
por: Glerum, Pieter J., et al.
Publicado: (2020)

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
por: Sablerolles, Roos S.G., et al.
Publicado: (2022)

Pharmacovigilance Data as a Trigger to Identify Antimicrobial Resistance and Inappropriate Use of Antibiotics: A Study Using Reports from The Netherlands Pharmacovigilance Centre
por: Habarugira, Jean Marie Vianney, et al.
Publicado: (2021)

Standardized guinea pig model for Q fever vaccine reactogenicity
por: Baeten, Laurie A., et al.
Publicado: (2018)

Can reactogenicity predict immunogenicity after COVID-19 vaccination?
por: Hwang, Young Hoon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j2kof8lienicbefq2iorli04ft